- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (195)
7 result(s) found for: Duction.
Displaying page 1 of 1.
EudraCT Number: 2017-001158-33 | Sponsor Protocol Number: OZR-2016-34 | Start Date*: 2017-07-20 |
Sponsor Name:The Rotterdam Eye Hospital | ||
Full Title: A pilot study towards a therapy with prednisolone encapsulated liposomes for the treatment of Graves’ Orbitopathy with reduced systemic steroid exposure | ||
Medical condition: Graves' Orbitopathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-001051-39 | Sponsor Protocol Number: FMG-MM-02 | Start Date*: 2012-11-15 | |||||||||||
Sponsor Name:Kuopio University Hospital, Clinic of Internal Medicine/Center of Medicine | |||||||||||||
Full Title: A prospective phase II study to assess immunophenotypic remission after three-drug in-duction followed by randomized stem cell mobilization, autologous stem cell transplantation and lenalidomide ma... | |||||||||||||
Medical condition: Multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000780-24 | Sponsor Protocol Number: MOR202C103 | Start Date*: 2019-09-24 | |||||||||||
Sponsor Name:MorphoSys AG | |||||||||||||
Full Title: A Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in anti-PLA2R antibody positive Membranous Nephropathy (aMN) - M-PLACE | |||||||||||||
Medical condition: Primary (anti-PLA2R antibody positive) Membranous Nephropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) ES (Completed) BE (Completed) FR (Completed) IT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004676-35 | Sponsor Protocol Number: RVT-1401-2001 | Start Date*: 2019-10-23 | |||||||||||
Sponsor Name:Immunovant Sciences GmbH | |||||||||||||
Full Title: ASCEND GO2: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study of RVT-1401 for the Treatment of Patients with Active, Moderate to Severe Graves’ Ophthalmopathy | |||||||||||||
Medical condition: Graves´Ophthalmopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000760-21 | Sponsor Protocol Number: GMALL-EVOLVE | Start Date*: 2023-03-28 | |||||||||||
Sponsor Name:Goethe-University | |||||||||||||
Full Title: A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy of ponatinib versus imatinib in combination with low-inte... | |||||||||||||
Medical condition: De novo Philadelphia-Chromosome positive acute lymphoblastic leukemia (Ph+ALL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000580-40 | Sponsor Protocol Number: CLL2-BAG | Start Date*: 2015-04-23 | |||||||||||
Sponsor Name:University of Cologne | |||||||||||||
Full Title: A prospective, open-label, multicentre phase-II-trial to evaluate the efficacy and safety of a sequential regimen of Bendamustine followed by GA101 (Obinutuzumab) and ABT-199 (Venetoclax) followed ... | |||||||||||||
Medical condition: Fit and unfit patients with previously untreated or relapsed/refractory CLL requiring treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003191-12 | Sponsor Protocol Number: TUD-2DAUNO-058 | Start Date*: 2014-01-31 | ||||||||||||||||||||||||||
Sponsor Name:Technische Universität Dresden | ||||||||||||||||||||||||||||
Full Title: Randomized comparison between two dose levels of daunorubicin and between one versus two cycles of in-duction therapy for adult patients with acute myeloid leukemia ≤65 years | ||||||||||||||||||||||||||||
Medical condition: Newly diagnosed AML other than acute promyelocytic leukemia (APL) according to WHO criteria, i.e. bone marrow aspirate or biopsy must contain ≥20% blasts of all nucleated cells or differential bloo... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) CZ (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
